Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

9064 items
8:18 AM, Sep 20, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest ablating meningeal lymphatic vessels with Visudyne verteporfin could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna of Visudyne followed...
8:18 AM, Sep 20, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1, the...
8:18 AM, Sep 20, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection Mouse studies identified a member of the arylomycin class of bacterial lepB-inhibiting antibiotics that could help treat multidrug resistant (MDR) Gram-negative bacterial infections. Chemical synthesis and in vitro assays of arylomycin...
8:17 AM, Sep 20, 2018  |  BC Innovations | Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest inhibiting DDIT3 or PERK could help treat hearing loss. In a mouse model of genetic hearing loss, systemic knockout of DDIT3 decreased hearing loss compared with normal DDIT3 expression. In...
12:37 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a tool...
12:36 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture studies identified a pteridinylbenzamide-based dual PLK1/BRD4 inhibitor that could help treat AML. Chemical synthesis and screening of analogs of a pteridinylbenzamide-based tool compound PLK1 inhibitor in enzyme activity assays...
12:35 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting HspD1 could help treat glioblastoma multiforme (GBM). In glioma and GBM patients, high tumor levels of HspD1 correlated with poor survival. In a...
12:34 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease

Indication: Rheumatoid arthritis (RA) In vitro and mouse studies suggest neutrophil plasma membrane-based nanoparticles could help treat RA. The nanoparticles consist of a poly(lactic-co-glycolic acid) (PLGA) core coated with activated primary human peripheral blood neutrophil-derived plasma...
12:34 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest inhibiting NFKB2 in combination with radiotherapy could help treat cancer. In glioblastoma patients treated with radiotherapy, high postmortem levels of NFKB2 mRNA in brain tissue...
12:34 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat contact hypersensitivity. The fusion consists of a 28-amino acid, cell-penetrating peptide from the N-terminus of Drosophila antennapedia (Antp) and...

Pages